About
Technology
Issues
FAQ
Links
Official Page
Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.